Acquired hemophilia A (AHA) is a rare bleeding disorder in which acquired autoantibodies
to endogenous factor VIII (FVIII) decrease FVIII activity and lead to a bleeding phenotype. A …

Acquired haemophilia A (AHA) is a rare bleeding disorder caused by autoantibodies against
human factor VIII (hFVIII). OBI‐1 is an investigational, B‐domain deleted, recombinant FVIII …

Introduction Acquired haemophilia A (AHA) is a rare, often severe, auto‐immune bleeding
disorder caused by the development of inhibitory antibodies (inhibitors) to factor VIII (FVIII) …

Introduction A recombinant porcine factor VIII B‐domain‐deleted product (rp FVIII; OBIZUR,
Baxalta Incorporated, Deerfield, IL 60015, USA) was recently approved for treatment of …

Recombinant porcine factor VIII (rpFVIII; Obizur, Susoctocog-alfa) was commissioned by
NHS England in June 2018 as a first line treatment option for actively bleeding patients with …

Background Recombinant porcine factor VIII (rpFVIII, OBI‐1, susoctocog alfa) is used for the
treatment of acute bleeds in patients with acquired hemophilia A (AHA). Inhibitors in AHA …

Acquired haemophilia A (AHA) is a rare, serious bleeding disorder most often encountered
in elderly patients. The mainstay of haemostatic management is with bypassing agents …

The most serious complication of factor VIII (FVIII) replacement therapy is the occurrence of
anti‐FVIII alloantibodies that can strongly reduce or abolish the effect of human FVIII …

Acquired hemophilia A is a rare autoimmune disorder caused by an autoantibody (inhibitor)
to factor VIII (FVIII) that interferes with its coagulant function and predisposes to severe …

Abstract Introduction Acquired haemophilia A (AHA) is a rare bleeding disorder caused by
development of auto‐antibodies to endogenous coagulation factor VIII (FVIII). Recombinant …